NO20062263L - Fremgangsmate for fremstilling av kalsiumsaltet til Rosuvatatin, (E)-7-[4-(4-fluorfenyl) -6-isopropyl-2-[metyl (metylsulfonyl) amino]pyrimidin -5-yl] (3R, 5S)-3,5-dihydroksyhept-6-ensyre samt - Google Patents

Fremgangsmate for fremstilling av kalsiumsaltet til Rosuvatatin, (E)-7-[4-(4-fluorfenyl) -6-isopropyl-2-[metyl (metylsulfonyl) amino]pyrimidin -5-yl] (3R, 5S)-3,5-dihydroksyhept-6-ensyre samt

Info

Publication number
NO20062263L
NO20062263L NO20062263A NO20062263A NO20062263L NO 20062263 L NO20062263 L NO 20062263L NO 20062263 A NO20062263 A NO 20062263A NO 20062263 A NO20062263 A NO 20062263A NO 20062263 L NO20062263 L NO 20062263L
Authority
NO
Norway
Prior art keywords
dihydroxyhept
methylsulfonyl
pyrimidin
fluorophenyl
isopropyl
Prior art date
Application number
NO20062263A
Other languages
English (en)
Norwegian (no)
Inventor
Tetsuo Okada
Patrick Dermot David Laffan
John Horbury
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29595716&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062263(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20062263L publication Critical patent/NO20062263L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20062263A 2003-10-24 2006-05-19 Fremgangsmate for fremstilling av kalsiumsaltet til Rosuvatatin, (E)-7-[4-(4-fluorfenyl) -6-isopropyl-2-[metyl (metylsulfonyl) amino]pyrimidin -5-yl] (3R, 5S)-3,5-dihydroksyhept-6-ensyre samt NO20062263L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0324791.3A GB0324791D0 (en) 2003-10-24 2003-10-24 Chemical process
PCT/GB2004/004481 WO2005042522A1 (en) 2003-10-24 2004-10-22 Process for the manufacture of the calcium salt of rosuvatatin (e)-7-`4- (4-fluorophenyl) -6-isopropyl-2-`methyl (methylsulfonyl) amino ! pyrimidin -5-yl ! (3r, 5s) -3, 5-dihydroxyhept-6-enoic acid and crystalline intermediates thereof

Publications (1)

Publication Number Publication Date
NO20062263L true NO20062263L (no) 2006-05-19

Family

ID=29595716

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062263A NO20062263L (no) 2003-10-24 2006-05-19 Fremgangsmate for fremstilling av kalsiumsaltet til Rosuvatatin, (E)-7-[4-(4-fluorfenyl) -6-isopropyl-2-[metyl (metylsulfonyl) amino]pyrimidin -5-yl] (3R, 5S)-3,5-dihydroksyhept-6-ensyre samt

Country Status (28)

Country Link
US (2) US20070255060A1 (ru)
EP (2) EP2272842A1 (ru)
JP (3) JP2007509119A (ru)
KR (1) KR20060132829A (ru)
CN (2) CN101654453B (ru)
AR (1) AR046191A1 (ru)
AU (1) AU2004285750B2 (ru)
BR (1) BRPI0415681A (ru)
CA (1) CA2543358A1 (ru)
CY (1) CY1114145T1 (ru)
DK (1) DK1682536T3 (ru)
ES (1) ES2404693T3 (ru)
GB (1) GB0324791D0 (ru)
IL (1) IL175086A0 (ru)
IS (1) IS8478A (ru)
MY (1) MY146002A (ru)
NO (1) NO20062263L (ru)
NZ (1) NZ547094A (ru)
PL (1) PL1682536T3 (ru)
PT (1) PT1682536E (ru)
RU (1) RU2372349C2 (ru)
SA (1) SA04250425B1 (ru)
SI (1) SI1682536T1 (ru)
TW (1) TWI344957B (ru)
UA (1) UA83076C2 (ru)
UY (1) UY28577A1 (ru)
WO (1) WO2005042522A1 (ru)
ZA (1) ZA200603173B (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) * 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
AR034772A1 (es) 2001-07-13 2004-03-17 Astrazeneca Uk Ltd Preparacion de los compuestos de aminopirimidina
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
ATE448209T1 (de) 2002-12-16 2009-11-15 Astrazeneca Uk Ltd Verfahren zur herstellung von pyrimidinverbindungen
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
HU227120B1 (hu) * 2005-05-26 2010-07-28 Richter Gedeon Nyrt Eljárás rosuvastatin kalciumsójának elõállítására új intermediereken keresztül
EP2508514B1 (en) 2005-06-24 2017-10-18 LEK Pharmaceuticals d.d. Process for preparing amorphous rosuvastatin calcium free of impurities
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
US8455640B2 (en) 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
US8404841B2 (en) 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
WO2008053334A2 (en) * 2006-10-31 2008-05-08 Aurobindo Pharma Limited An improved process for preparing rosuvastatin calcium
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
CA2677809A1 (en) * 2007-02-08 2008-08-14 Aurobindo Pharma Limited An improved process for preparation of rosuvastatin calcium
US20090069563A1 (en) * 2007-07-12 2009-03-12 Valerie Niddam-Hildesheim Rosuvastatin intermediates and their preparation
EP2022784A1 (en) 2007-08-08 2009-02-11 LEK Pharmaceuticals D.D. Process for the preparation of methyl ester of rosuvastatin
US8793497B2 (en) * 2008-05-09 2014-07-29 Qualcomm Incorporated Puzzle-based authentication between a token and verifiers
EP2298745B1 (en) 2008-05-27 2014-09-03 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
BRPI1005147A2 (pt) 2009-01-15 2019-09-24 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag processo de preparação de sais de rosuvastatina
EP2387561A4 (en) 2009-01-19 2012-07-25 Msn Lab Ltd IMPROVED METHOD FOR THE PRODUCTION OF HIGH-PURITY (3R, 5S) -7- [2-CYCLOPROPYL-4- (4-FLUORPHENYL) CHINOLIN-3-YL] -3,5-DIHYDROXY-6 (E) -HEPTENIC ACID AND PHARMACEUTICAL ACCEPTABLE SALTS THEREOF
US8846915B2 (en) 2009-08-17 2014-09-30 Aurobindo Pharma Ltd. Process for the manufacture of rosuvastatin calcium using crystalline rosuvastatin ethyl ester
EP2336116A1 (en) * 2009-12-16 2011-06-22 LEK Pharmaceuticals d.d. Process for the preparation of key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
CN102219749B (zh) * 2010-04-14 2013-07-17 上海京新生物医药有限公司 一种制备瑞苏伐他汀钙的方法
AU2011243948B2 (en) 2010-04-23 2014-07-17 Sun Pharmaceutical Industries Limited Novel intermediates for the preparation of HMG-CoA reductase inhibitors
CN105153010B (zh) 2010-07-01 2018-06-08 柳韩洋行 HMG-CoA还原酶抑制剂及其中间体的制备方法
HU230987B1 (hu) * 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
US9126975B2 (en) * 2011-01-18 2015-09-08 Dsm Sinochem Pharmaceuticals Netherlands B.V. Process for the preparation of statins in the presence of base
CN103848790B (zh) * 2012-12-05 2016-08-03 安徽省庆云医药化工有限公司 瑞舒伐他汀酯的晶型及其制备方法
CN103724278B (zh) * 2013-12-12 2019-03-29 江苏阿尔法药业有限公司 他汀类中间体及其衍生物的制备方法
JP6596339B2 (ja) 2014-02-06 2019-10-23 株式会社エーピーアイ コーポレーション ロスバスタチンカルシウム及びその中間体の製造方法
CN105153040B (zh) * 2015-10-15 2018-04-13 江苏师范大学 瑞舒伐他汀钙新晶型及其制备方法
CN105461636A (zh) * 2015-12-30 2016-04-06 安徽美诺华药物化学有限公司 一种瑞舒伐他汀甲酯的合成方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645858A (en) 1982-03-22 1987-02-24 G. D. Searle & Co. Pentanedioic acid derivatives
DE3741509A1 (de) * 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
AU3214689A (en) 1988-10-06 1990-05-01 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5026698A (en) * 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5278313A (en) 1992-03-27 1994-01-11 E. R. Squibb & Sons, Inc. Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
SG44830A1 (en) 1992-07-02 1997-12-19 Hoechst Ag Process for preparing tert-butyl 93R,5S) -6 Hydroxy-3,5-O-Isopropylidene-3, 5-Dihydroxyhexanoate
KR100431038B1 (ko) 1995-07-17 2004-05-12 워너-램버트 캄파니 엘엘씨 결정질[ｒ-(ｒ*,ｒ*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1ｈ-피롤-1-헵탄산 헤미 칼슘염 (아토르바스타틴)
US6278001B1 (en) 1995-11-28 2001-08-21 L'oréal Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
WO1997049681A1 (en) 1996-06-24 1997-12-31 Astra Aktiebolag (Publ) Polymorphic compounds
SI20070A (sl) 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
KR100672269B1 (ko) 1998-12-10 2007-01-23 카네카 코포레이션 심바스타틴의 제조 방법
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
AU7717500A (en) 1999-09-30 2001-04-30 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
CZ20021642A3 (cs) 1999-11-17 2003-05-14 Teva Pharmaceutical Industries Ltd. Polymorfní formy atorvastatinu vápenatého
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
WO2001072706A1 (en) 2000-03-28 2001-10-04 Biocon India Limited Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
GB0011120D0 (en) * 2000-05-09 2000-06-28 Avecia Ltd Process
GB0011163D0 (en) 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
NL1015744C2 (nl) * 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
JP3737801B2 (ja) 2000-10-05 2006-01-25 テバ ジョジセルジャール レースベニュタールシャシャーグ プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウム、並びにそれを含む組成物
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
HUP0303555A3 (en) 2000-11-16 2005-08-29 Teva Pharma Hydrolysis of [r(r
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
NL1017548C2 (nl) 2001-03-09 2002-09-10 Synthon Bv Een lactonisatie proces.
IN190564B (ru) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
BR0209942A (pt) 2001-06-06 2004-03-30 Bristol Myers Squibb Co Processo para preparar diol-sulfonas quirais e inibidores de diidroxiácido hmg coa redutase
AR034772A1 (es) * 2001-07-13 2004-03-17 Astrazeneca Uk Ltd Preparacion de los compuestos de aminopirimidina
HUP0500616A3 (en) * 2001-08-16 2011-07-28 Teva Pharma Processes for preparing calcium salt forms of statins
WO2003018555A1 (en) 2001-08-22 2003-03-06 Ciba Speciality Chemicals Holding Inc. Process for the preparation of indole derivatives
CA2459926A1 (en) 2001-09-24 2003-04-03 Merck & Co., Inc. Screening and selection methods for statin drug combinations
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
GB0204129D0 (en) 2002-02-21 2002-04-10 Novartis Ag Process for the manufacture of organic compounds
KR100511533B1 (ko) * 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
AR039836A1 (es) 2002-05-21 2005-03-02 Ranbaxy Lab Ltd Proceso para la preparacion de un aldehido de pirimidina util para la preparacion de rosuvastatina
EP1375493A1 (en) * 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
CN1742000A (zh) 2002-12-10 2006-03-01 兰贝克赛实验室有限公司 制备若舒伐他汀的方法
ATE448209T1 (de) 2002-12-16 2009-11-15 Astrazeneca Uk Ltd Verfahren zur herstellung von pyrimidinverbindungen
AU2004228607B2 (en) 2003-04-11 2011-01-27 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
WO2004103977A2 (en) 2003-05-21 2004-12-02 Ciba Specialty Chemicals Holding Inc. Process for the preparation of pyrimidine derivatives
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
WO2005005384A1 (en) 2003-07-15 2005-01-20 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
CA2537271A1 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
CN1886383A (zh) * 2003-10-22 2006-12-27 兰贝克赛实验室有限公司 无定形罗苏伐他汀钙的制备方法
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
DE10352659B4 (de) 2003-11-11 2007-09-13 Ratiopharm Gmbh Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
WO2005077916A1 (en) 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
WO2005051921A1 (en) 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
KR100887264B1 (ko) 2003-12-02 2009-03-06 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 특성화를 위한 기준 표준물
WO2005054207A1 (en) 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
US20050159615A1 (en) 2003-12-24 2005-07-21 Entire Interest. Process for preparation of statins with high syn to anti ratio
CZ200486A3 (cs) 2004-01-16 2005-08-17 Zentiva, A.S. Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny
WO2005077917A1 (en) 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Amorphous salts of rosuvastatin
US7241800B2 (en) * 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
GB0406757D0 (en) 2004-03-26 2004-04-28 Avecia Ltd Process and compounds
US7161004B2 (en) 2004-06-21 2007-01-09 Dr. Reddy's Laboratories Limited Processes to produce intermediates for rosuvastatin
US7179916B2 (en) 2004-07-13 2007-02-20 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin
US20080234302A1 (en) 2004-09-27 2008-09-25 Mohammad Rafeeq Novel Processes for Preparing Amorphous Rosuvastatin Calcium and a Novel Polymorphic Form of Rosuvastatin Sodium
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
JP2008528542A (ja) 2005-01-31 2008-07-31 チバ ホールディング インコーポレーテッド ロスバスタチンカルシウム塩の結晶形
CA2498978A1 (en) 2005-02-28 2006-08-28 Apotex Pharmachem Inc. An improved process for the preparation of atorvastatin and intermediates
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
JP4614238B2 (ja) * 2006-07-14 2011-01-19 ルネサスエレクトロニクス株式会社 Ｒｆ電力増幅装置
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process

Also Published As

Publication number Publication date
EP1682536A1 (en) 2006-07-26
ES2404693T3 (es) 2013-05-28
JP2008044948A (ja) 2008-02-28
EP2272842A1 (en) 2011-01-12
UY28577A1 (es) 2005-06-30
NZ547094A (en) 2009-05-31
PL1682536T3 (pl) 2013-08-30
ZA200603173B (en) 2007-07-25
IL175086A0 (en) 2006-08-20
EP1682536B1 (en) 2013-02-27
KR20060132829A (ko) 2006-12-22
CN1898233A (zh) 2007-01-17
US9371291B2 (en) 2016-06-21
SI1682536T1 (sl) 2013-07-31
MY146002A (en) 2012-06-15
RU2006117337A (ru) 2007-12-10
GB0324791D0 (en) 2003-11-26
AU2004285750B2 (en) 2008-03-13
BRPI0415681A (pt) 2006-12-19
US20070255060A1 (en) 2007-11-01
TWI344957B (en) 2011-07-11
AR046191A1 (es) 2005-11-30
CA2543358A1 (en) 2005-05-12
CY1114145T1 (el) 2016-07-27
TW200523256A (en) 2005-07-16
JP2007509119A (ja) 2007-04-12
RU2372349C2 (ru) 2009-11-10
WO2005042522A1 (en) 2005-05-12
JP2008024712A (ja) 2008-02-07
PT1682536E (pt) 2013-05-06
UA83076C2 (en) 2008-06-10
IS8478A (is) 2006-05-22
DK1682536T3 (da) 2013-05-06
CN101654453A (zh) 2010-02-24
AU2004285750A1 (en) 2005-05-12
US20110301348A1 (en) 2011-12-08
CN101654453B (zh) 2012-07-04
SA04250425B1 (ar) 2009-08-11
CN1898233B (zh) 2012-06-13
HK1092462A1 (en) 2007-02-09

Similar Documents

Publication Publication Date Title
MY146002A (en) Process for the manufacture of the calcium salt of rosuvatatin (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl) amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and crystalline intermediates thereof
NO20013368L (no) Krystallinsk bis((E)-7-(4-(4-fluorfenyl)-6-isopropyl-2- (metyl(metylsulfonyl)amino)pyrimidin-5-yl)(3R,5S)-3,5-dihydroksyhept-6-ensyre)kalsiumsalt
NO20023853D0 (no) Krystallinske salter av 7-[4-(fluorfenyl)-6-isopropyl-2- [metyl(metylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroksyhept-6-ensyre
BR0311195A (pt) Processo de preparação de rosuvastatina
MY142615A (en) Crystalline form of bis [ (e)-7-4(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r, 5s)-3,5-dihydroxyhept-6 -enoic acid] calcium salt
WO2009157014A3 (en) A process for preparing hmg-coa reductase inhibitors and intermediates
EP1902036B1 (en) Process for the preparation of rosuvastatin and intermediates
PE20061057A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE HMG CoA REDUCTASA
PL1704144T3 (pl) Sposób wytwarzania soli wapniowej kwasu (E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo](3R,5S)-3,5-dihydroksy-6-heptenowego
NO330965B1 (no) Fremgangsmate for fremstilling av substituerte imidazolderivater, mellomprodukter anvendt i fremgangsmaten samt fremgangsmate for fremstilling av mellomprodukt
AR043594A1 (es) Un procedimiento para la preparacion de la sal de calcio del acido (e)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil(metil-sulfonil)amino]pirimidin-5-il] (3r,5s)-3,5-dihidroxihept-6-enoico y compuesto utilizable en dicho procedimiento

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application